Trustpilot

You MUST be 18 or over to shop with Vape Emporium

How UK Employers Should Investigate and Confirm a Positive Saliva Cotinine Test for Suspected Workplace Vaping (2026 Guide)

Published on
drug-testing , vaping-policy , workplace-safety

Introduction — the problem in brief

Suspected workplace vaping can create safety, comfort and policy-compliance issues for employers. When an on-site saliva cotinine screen returns a presumptive positive, employers face a legal and practical problem: how to confirm the result fairly, rapidly and in line with UK rules. This guide gives a step-by-step, legally compliant protocol for 2026, explains common pitfalls and offers prevention tips so you can handle cases with confidence and minimal risk.

Problem statement

Saliva cotinine screens are increasingly used to detect recent nicotine exposure, but an on-site positive is only presumptive. Employers who act on a presumptive positive without proper consent, confirmatory testing and documented process risk unfair dismissal claims, discrimination complaints and data protection breaches. You need a clear, documented, proportionate protocol that respects employee rights and statutory standards.

Why this happens — common causes of a presumptive positive

  • Recent vaping or smoking: Even nicotine from e‑cigarettes produces cotinine in saliva.
  • Nicotine replacement therapy (NRT): Patches, gum or lozenges produce cotinine similar to vaping.
  • Second‑hand exposure: High levels of passive exposure can sometimes raise saliva cotinine near low cut‑offs.
  • Testing device issues or contamination: Faulty on‑site kits, improper collection or handling can give false presumptive positives.
  • Timing and cut‑off choice: Providers commonly use thresholds around ~30 ng/mL to reduce false positives; different thresholds change sensitivity.

Legally critical facts you must follow

  • Consent: Obtain explicit, informed consent before testing. This is usually gained via contract clauses or a clearly communicated written policy. Employees cannot be compelled to give a sample otherwise.
  • Presumptive vs confirmatory: On‑site saliva screens are presumptive only. Send any positive to a UKAS‑accredited laboratory for confirmatory GC‑MS or LC‑MS/MS testing before any disciplinary action.
  • Detection window: Saliva cotinine is typically detectable for up to ~4 days after nicotine use (longer for heavy users) — different matrices (urine, blood, hair) have different windows.
  • Cut‑offs matter: Many providers use a cut‑off around 30 ng/mL to reduce false positives from second‑hand smoke. Choose and document your threshold for legal defensibility.
  • Data protection & chain of custody: Treat results as sensitive personal data under UK GDPR. Use authenticated collection devices, documented transport to the UKAS lab and strict recordkeeping.

Step‑by‑step protocol (operational checklist)

  • Step 1 — Policy & consent (proactive):
    • Ensure your workplace policy explains who may be tested, under what circumstances (eg. reasonable suspicion, safety critical roles), what substances are screened, consequences and the appeals process.
    • Obtain explicit written consent as part of contract or separate signed policy acknowledgement. Keep a copy accessible.
  • Step 2 — Establish reasonable suspicion (documented):
    • Record objective indicators (smell of vaping, observed vaping in prohibited area, safety incident potentially linked to impairment). Avoid vague or discriminatory reasons.
    • Decide if testing is proportionate given role and sector rules (eg. transport, construction or safety‑critical positions may warrant lower tolerance).
  • Step 3 — On‑site presumptive screen:
    • Only use accredited screening kits operated by trained staff. Explain the process, reconfirm consent, and collect the sample in the presence of a witness.
    • Record kit batch number, time, collector identity and sign the collection sheet.
  • Step 4 — If presumptive positive: preserve and send for confirmatory testing:
    • Do not take disciplinary action based on the on‑site result alone. Seal the sample using authenticated collection devices and follow your documented chain‑of‑custody procedure.
    • Send the sample to a UKAS‑accredited laboratory for confirmatory GC‑MS or LC‑MS/MS testing. Record transport details and obtain lab acceptance confirmation.
  • Step 5 — Record declarations and consider alternative assessments:
    • Ask the worker to declare recent nicotine use, including e‑cigarettes and NRT (patches, gum, lozenges). NRT will produce cotinine and must be recorded.
    • If you need to distinguish recent smoking from nicotine replacement or vaping for safety reasons, consider complementary measures such as carbon monoxide (CO) monitoring — but only with consent and documented rationale.
  • Step 6 — Wait for confirmatory results and medical/HR interview:
    • On receipt of UKAS lab confirmation, arrange a confidential meeting with occupational health or an HR representative and the employee to review the confirmed result, declarations and mitigating factors.
    • Only after this process should you consider proportionate disciplinary or safety actions, giving the employee chance to appeal.

Troubleshooting tips — common issues and fixes

  • False positives from passive exposure: If the presumptive result is near the cut‑off, ask for additional details about exposure and wait for confirmatory GC‑MS. Consider whether your chosen cut‑off is appropriate.
  • Device malfunction or poor sample: If chain‑of‑custody or kit integrity is in doubt, obtain a fresh sample with correct documentation.
  • Declared NRT use: If the employee declares NRT, note the brand and timing; confirmatory lab results often quantify cotinine and can be interpreted alongside the declaration.
  • Delays in lab processing: Use UKAS labs with clear turnaround times in contracts; keep employees informed to reduce stress and complaints.

Prevention & policy tips

  • Keep your policy up to date and sector‑specific — for instance, transport or construction may need stricter rules due to safety duties.
  • Train managers to document reasonable suspicion objectively and to respect employee privacy and consent requirements.
  • Communicate how nicotine use (including vaping and NRT) is treated. Many employees use nicotine products — that’s not automatically misconduct unless policy or safety rules are breached.
  • Provide support: offer smoking‑cessation support and signpost to occupational health. If employees use nicotine products, they may benefit from quit resources rather than punitive measures. Note that many vape liquids and nicotine shots are legally available; for example, employers should be aware staff might use nicotine e‑liquids (such as longfills with nicotine shots) or disposable cartridges outside work hours.
  • Designate a clear appeals route and maintain secure records in line with UK GDPR.

Conclusion — fair, defensible and humane

Handling suspected workplace vaping requires a balance of safety, legal compliance and fairness. Follow a documented, consented process: use on‑site screens only as presumptive tools, preserve chain of custody, send positives to a UKAS‑accredited lab for GC‑MS/LC‑MS/MS confirmation, record declared NRT or e‑cigarette use, and complete a medical/HR interview before any disciplinary decision. That approach reduces legal risk, protects employee rights and keeps your workplace safe and orderly.

Need a sample testing policy or consent form tailored to your sector? Contact occupational health or legal counsel to produce a template that fits your business and safety obligations.

Back to Vape Emporium Blog